Dual Stimuli-Responsive Gemcitabine-Conjugated Alginate-Chitosan Nanoparticles for Triple-Negative Breast Cancer Therapy: A Smart Approach
Bioconjugate Chemistry · 17.09.2025 · 36 (9) · 2037-2053
DOI: 10.1021/acs.bioconjchem.5c00334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 01.09.2025. Verfasst von Tarun Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Sciences - Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Man…. Hauptthemen laut MEDLINE: Deoxycytidine, Chitosan, Alginates, Nanoparticles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Among the available chemotherapeutic agents, gemcitabine (GEM) has demonstrated significant efficacy against various cancers. Nevertheless, its clinical application is restricted due to its poor pharmacokinetic properties, highlighting the need for improved drug delivery strategies. Here, Dual stimuli-responsive hybrid polymeric nanoparticles conjugating GEM have been developed using a chitosan alginate biopolymer. The polymers anchored GEM via hydrazone and disulfide linkers, enabling dual stimuli-responsive drug release in tumors by leveraging pH variations and elevated glutathione (GSH) levels. This innovative nanoplatform enhances GEM systemic exposure, stability, and therapeutic efficacy while minimizing systemic toxicity. The Alg/Chi-GEM nanoparticles (NPs) were comprehensively characterized for their physicochemical properties via 1H NMR, infrared spectroscopy, GPC, DSC, and particle size analysis, along with stimuli-responsive drug release and hemolysis studies to confirm their robustness. The therapeutic potential of the nanoplatform was rigorously assessed in various breast cancer cell lines, including 4T1, MCF-7, and MDA-MB-231 cells, where the NPs demonstrated superior cellular uptake, enhanced cytotoxicity, and efficient apoptosis induction through DNA fragmentation, ROS generation, mitochondrial depolarization, and G2/M phase arrest. In vivo studies using 4T1-Luc tumor-bearing mice further validated their antitumor efficacy, showing significant tumor growth inhibition at a 10 mg/kg GEM equivalent dose with reduced toxicity compared to free GEM. These findings indicated that Alg/Chi-GEM NPs, as a next-generation nanomedicine, offer a safer, more effective approach to overcoming gemcitabine resistance and enhancing breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Sciences - Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Medchal District, Hyderabad, Telangana 500078, India.
- Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Sciences - Pilani, Hyderabad Campus, Jawahar Nagar, Kapra mandal, Medchal District, Hyderabad, Telangana 500078, India.
ORCID-Profile: Swati Biswas, Balaram Ghosh
Förderung
- Indian Council of Medical Research
Zitieren
APA
Patel, T., Himaja, A., Biswas, S., & Ghosh, B. (2025). Dual Stimuli-Responsive Gemcitabine-Conjugated Alginate-Chitosan Nanoparticles for Triple-Negative Breast Cancer Therapy: A Smart Approach. Bioconjugate Chemistry, 36(9), 2037-2053. https://doi.org/10.1021/acs.bioconjchem.5c00334
Vancouver
Patel T, Himaja A, Biswas S, Ghosh B. Dual Stimuli-Responsive Gemcitabine-Conjugated Alginate-Chitosan Nanoparticles for Triple-Negative Breast Cancer Therapy: A Smart Approach. Bioconjugate Chemistry. 2025;36(9):2037-2053. doi:10.1021/acs.bioconjchem.5c00334
BibTeX
@article{Patel2025,
author = {Patel, Tarun and Himaja, Ambati and Biswas, Swati and Ghosh, Balaram},
title = {Dual Stimuli-Responsive Gemcitabine-Conjugated Alginate-Chitosan Nanoparticles for Triple-Negative Breast Cancer Therapy: A Smart Approach},
journal = {Bioconjugate Chemistry},
year = {2025},
volume = {36},
number = {9},
pages = {2037--2053},
doi = {10.1021/acs.bioconjchem.5c00334}
}
EUVIMED